Subcellular and metabolic examination of amyloid-β peptides in Alzheimer disease pathogenesis: Evidence for Aβ25-35

Experimental Neurology

Volumn 221, Issue 1, 2010, Pages 26-37

  Kaminsky, Yury G ^a   Marlatt, Michael W ^b   Smith, Mark A ^c   Kosenko, Elena A ^a  

^a INSTITUTE OF THEORETICAL AND EXPERIMENTAL BIOPHYSICS   (Russian Federation)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Amyloid ; Cerebellum; Cytosol; Hippocampus; Mitochondria; Neocortex; Nuclei

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[25-35]; ANTIOXIDANT; CALCIUM; DIZOCILPINE; DNA; LYSOSOME ENZYME; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OLIGOMER; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN CELL; BRAIN TOXICITY; CALCIUM HOMEOSTASIS; CELL COMPARTMENTALIZATION; CELL DAMAGE; CELL METABOLISM; CELL NUCLEUS; CELLULAR DISTRIBUTION; CEREBELLUM; CYTOSOL; DISEASE COURSE; DRUG MECHANISM; ENZYME ACTIVATION; HIPPOCAMPUS; HUMAN; MITOCHONDRION; MOLECULAR MECHANICS; NEOCORTEX; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PROCESSING; PROTEIN STABILITY; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; APOPTOSIS; BRAIN; CALCIUM; CALCIUM SIGNALING; HUMANS; MITOCHONDRIA; NEURONS; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; RECEPTORS, N-METHYL-D-ASPARTATE; SUBCELLULAR FRACTIONS;

EID: 72749122338     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2009.09.005     Document Type: Review

References (178)

1. Adamec E., Mohan P., Vonsattel J.P., and Nixon R.A. Calpain activation in neurodegenerative diseases: confocal immunofluorescence study with antibodies specifically recognizing the active form of calpain 2. Acta Neuropathol. 104 (2002) 92-104
2. Aksenov M.Y., Aksenova M.V., Markesbery W.R., and Butterfield D.A. Amyloid beta-peptide (1-40)-mediated oxidative stress in cultured hippocampal neurons. Protein carbonyl formation, CK BB expression, and the level of Cu, Zn, and Mn SOD mRNA. J. Mol. Neurosci. 10 (1998) 181-192
3. Aleardi A.M., Benard G., Augereau O., Malgat M., Talbot J.C., Mazat J.P., Letellier T., Dachary-Prigent J., Solaini G.C., and Rossignol R. Gradual alteration of mitochondrial structure and function by beta-amyloids: importance of membrane viscosity changes, energy deprivation, reactive oxygen species production, and cytochrome c release. J. Bioenerg. Biomembr. 37 (2005) 207-225
4. Aliev G., Smith M.A., de la Torre J.C., and Perry G. Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer's disease. Mitochondrion 4 (2004) 649-663
5. Aliyev, A., Chen, S.G., Seyidova, D., Smith, M.A., Perry, G., de la Torre, J., and Aliev, G., 2005. Mitochondria DNA deletions in atherosclerotic hypoperfused brain microvessels as a primary target for the development of Alzheimer's disease. J. Neurol. Sci. 229-230, 285-292.
6. Allen J.W., Eldadah B.A., Huang X., Knoblach S.M., and Faden A.I. Multiple caspases are involved in beta-amyloid-induced neuronal apoptosis. J. Neurosci. Res. 65 (2001) 45-53
7. Alnemri E.S., Livingston D.J., Nicholson D.W., Salvesen G., Thornberry N.A., Wong W.W., and Yuan J. Human ICE/CED-3 protease nomenclature. Cell 87 (1996) 171
8. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allg. Zeitschr. Psychiatr. 64 (1907) 146-148
9. Arrington D.D., Van Vleet T.R., and Schnellmann R.G. Calpain 10: a mitochondrial calpain and its role in calcium-induced mitochondrial dysfunction. Am. J. Physiol. Cell Physiol. 291 (2006) C1159-1171
10. Beck M., Bigl V., and Rossner S. Guinea pigs as a nontransgenic model for APP processing in vitro and in vivo. Neurochem. Res. 28 (2003) 637-644
11. Behl C., Davis J., Cole G.M., and Schubert D. Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem. Biophys. Res. Commun. 186 (1992) 944-950
12. Behl C., Davis J.B., Lesley R., and Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77 (1994) 817-827
13. Benzi G., and Moretti A. Are reactive oxygen species involved in Alzheimer's disease?. Neurobiol. Aging 16 (1995) 661-674
14. Berger N.A. Poly(ADP-ribose) in the cellular response to DNA damage. Radiat. Res. 101 (1985) 4-15
15. Bertram L., and Tanzi R.E. The current status of Alzheimer's disease genetics: what do we tell the patients?. Pharmacol. Res. 50 (2004) 385-396
16. Bird T.D. Genetic factors in Alzheimer's disease. N. Engl. J. Med. 352 (2005) 862-864
17. Bogdanovic N., Zilmer M., Zilmer K., Rehema A., and Karelson E. The Swedish APP670/671 Alzheimer's disease mutation: the first evidence for strikingly increased oxidative injury in the temporal inferior cortex. Dement. Geriatr. Cogn. Disord. 12 (2001) 364-370
18. Boldyrev A., Koudinov A., Berezov T., and Carpenter D.O. Amyloid-beta induced cell death is independent of free radicals. J. Alzheimers Dis. 6 (2004) 633-638 discussion 673-681
19. Boveris A. Mitochondrial production of superoxide radical and hydrogen peroxide. Adv. Exp. Med. Biol. 78 (1977) 67-82
20. Brigelius-Flohe R. Glutathione peroxidases and redox-regulated transcription factors. Biol. Chem. 387 (2006) 1329-1335
21. Budihardjo I., Oliver H., Lutter M., Luo X., and Wang X. Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol. 15 (1999) 269-290
22. Burkhard P.R., Fournier R., Mermillod B., Krause K.H., Bouras C., and Irminger I. Cerebrospinal fluid tau and Abeta42 concentrations in healthy subjects: delineation of reference intervals and their limitations. Clin. Chem. Lab. Med. 42 (2004) 396-407
23. Cafe C., Torri C., Bertorelli L., Angeretti N., Lucca E., Forloni G., and Marzatico F. Oxidative stress after acute and chronic application of beta-amyloid fragment 25-35 in cortical cultures. Neurosci. Lett. 203 (1996) 61-65
24. Callahan L.M., Vaules W.A., and Coleman P.D. Quantitative decrease in synaptophysin message expression and increase in cathepsin D message expression in Alzheimer disease neurons containing neurofibrillary tangles. J. Neuropathol. Exp. Neurol. 58 (1999) 275-287
25. Casley C.S., Canevari L., Land J.M., Clark J.B., and Sharpe M.A. Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J. Neurochem. 80 (2002) 91-100
26. Casoli T., Di Stefano G., Giorgetti B., Grossi Y., Balietti M., Fattoretti P., and Bertoni-Freddari C. Release of beta-amyloid from high-density platelets: implications for Alzheimer's disease pathology. Ann. N.Y. Acad. Sci. 1096 (2007) 170-178
27. Caspersen C., Wang N., Yao J., Sosunov A., Chen X., Lustbader J.W., Xu H.W., Stern D., McKhann G., and Yan S.D. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J. 19 (2005) 2040-2041
28. Cataldo A.M., and Nixon R.A. Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 3861-3865
29. Cataldo A.M., Barnett J.L., Pieroni C., and Nixon R.A. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J. Neurosci. 17 (1997) 6142-6151
30. Cheah K.S., and Chance B. The oxidase systems of Ascaris-muscle mitochondria. Biochim. Biophys. Acta 223 (1970) 55-60
31. Chen M., and Fernandez H.L. Mu-calpain is functionally required for alpha-processing of Alzheimer's beta-amyloid precursor protein. Biochem. Biophys. Res. Commun. 330 (2005) 714-721
32. Chen X., and Yan S.D. Mitochondrial Abeta: a potential cause of metabolic dysfunction in Alzheimer's disease. IUBMB Life 58 (2006) 686-694
33. Chen X., Stern D., and Yan S.D. Mitochondrial dysfunction and Alzheimer's disease. Curr. Alzheimer Res. 3 (2006) 515-520
34. Clark C.M., Xie S., Chittams J., Ewbank D., Peskind E., Galasko D., Morris J.C., McKeel Jr. D.W., Farlow M., Weitlauf S.L., Quinn J., Kaye J., Knopman D., Arai H., Doody R.S., DeCarli C., Leight S., Lee V.M., and Trojanowski J.Q. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch. Neurol. 60 (2003) 1696-1702
35. Colurso G.J., Nilson J.E., and Vervoort L.G. Quantitative assessment of DNA fragmentation and beta-amyloid deposition in insular cortex and midfrontal gyrus from patients with Alzheimer's disease. Life Sci. 73 (2003) 1795-1803
36. Corte E.D., and Stirpe F. The regulation of rat liver xanthine oxidase. Involvement of thiol groups in the conversion of the enzyme activity from dehydrogenase (type D) into oxidase (type O) and purification of the enzyme. Biochem. J. 126 (1972) 739-745
37. Crawford F., Suo Z., Fang C., and Mullan M. Characteristics of the in vitro vasoactivity of beta-amyloid peptides. Exp. Neurol. 150 (1998) 159-168
38. De Felice F.G., Velasco P.T., Lambert M.P., Viola K., Fernandez S.J., Ferreira S.T., and Klein W.L. Abeta oligomers induce neuronal oxidative stress through an N-methyl-d-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem. 282 (2007) 11590-11601
39. De Strooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., Von Figura K., and Van Leuven F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391 (1998) 387-390
40. Del Mar Martinez-Senac M., Villalain J., and Gomez-Fernandez J.C. Structure of the Alzheimer beta-amyloid peptide (25-35) and its interaction with negatively charged phospholipid vesicles. Eur. J. Biochem. 265 (1999) 744-753
41. Dippold W.G., Jay G., DeLeo A.B., Khoury G., and Old L.J. p53 transformation-related protein: detection by monoclonal antibody in mouse and human cells. Proc. Natl. Acad. Sci. U. S. A. 78 (1981) 1695-1699
42. Dorus S., Vallender E.J., Evans P.D., Anderson J.R., Gilbert S.L., Mahowald M., Wyckoff G.J., Malcom C.M., and Lahn B.T. Accelerated evolution of nervous system genes in the origin of Homo sapiens. Cell 119 (2004) 1027-1040
43. Dracheva S., Marras S.A., Elhakem S.L., Kramer F.R., Davis K.L., and Haroutunian V. N-methyl-d-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am. J. Psychiatry 158 (2001) 1400-1410
44. Francis R., McGrath G., Zhang J., Ruddy D.A., Sym M., Apfeld J., Nicoll M., Maxwell M., Hai B., Ellis M.C., Parks A.L., Xu W., Li J., Gurney M., Myers R.L., Himes C.S., Hiebsch R., Ruble C., Nye J.S., and Curtis D. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev. Cell 3 (2002) 85-97
45. Ganzer S., Arlt S., Schoder V., Buhmann C., Mandelkow E.M., Finckh U., Beisiegel U., Naber D., and Muller-Thomsen T. CSF-tau, CSF-Abeta1-42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer's disease: combination of CSF-tau and MMSE yields highest sensitivity and specificity. J. Neural. Transm. 110 (2003) 1149-1160
46. Garland J.M., and Rudin C. Cytochrome c induces caspase-dependent apoptosis in intact hematopoietic cells and overrides apoptosis suppression mediated by bcl-2, growth factor signaling, MAP-kinase-kinase, and malignant change. Blood 92 (1998) 1235-1246
47. Gelfanova V., Higgs R.E., Dean R.A., Holtzman D.M., Farlow M.R., Siemers E.R., Boodhoo A., Qian Y.W., He X., Jin Z., Fisher D.L., Cox K.L., and Hale J.E. Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry. Brief Funct. Genomic Proteomic 6 (2007) 149-158
48. Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R., and Vandekerckhove J. Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat. Biotechnol. 21 (2003) 566-569
49. Ghiso J., Calero M., Matsubara E., Governale S., Chuba J., Beavis R., Wisniewski T., and Frangione B. Alzheimer's soluble amyloid beta is a normal component of human urine. FEBS Lett. 408 (1997) 105-108
50. Ghiso J., Shayo M., Calero M., Ng D., Tomidokoro Y., Gandy S., Rostagno A., and Frangione B. Systemic catabolism of Alzheimer's Abeta40 and Abeta42. J. Biol. Chem. 279 (2004) 45897-45908
51. Goutte C., Tsunozaki M., Hale V.A., and Priess J.R. APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 775-779
52. Gray C.W., and Patel A.J. Neurodegeneration mediated by glutamate and beta-amyloid peptide: a comparison and possible interaction. Brain Res. 691 (1995) 169-179
53. Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L., Lieberburg I., Koo E.H., Schenk D., Teplow D.B., et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359 (1992) 322-325
54. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20 (1997) 154-159
55. Harkany T., Abraham I., Timmerman W., Laskay G., Toth B., Sasvari M., Konya C., Sebens J.B., Korf J., Nyakas C., Zarandi M., Soos K., Penke B., and Luiten P.G. Beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur. J. Neurosci. 12 (2000) 2735-2745
56. Harris M.E., Hensley K., Butterfield D.A., Leedle R.A., and Carney J.M. Direct evidence of oxidative injury produced by the Alzheimer's beta-amyloid peptide (1-40) in cultured hippocampal neurons. Exp. Neurol. 131 (1995) 193-202
57. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., and Evans D.A. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 60 (2003) 1119-1122
58. Hensley K., Carney J.M., Mattson M.P., Aksenova M., Harris M., Wu J.F., Floyd R.A., and Butterfield D.A. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 3270-3274
59. Horikawa Y., Oda N., Cox N.J., Li X., Orho-Melander M., Hara M., Hinokio Y., Lindner T.H., Mashima H., Schwarz P.E., del Bosque-Plata L., Oda Y., Yoshiuchi I., Colilla S., Polonsky K.S., Wei S., Concannon P., Iwasaki N., Schulze J., Baier L.J., Bogardus C., Groop L., Boerwinkle E., Hanis C.L., and Bell G.I. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat. Genet. 26 (2000) 163-175
60. Hughes E., Burke R.M., and Doig A.J. Inhibition of toxicity in the beta-amyloid peptide fragment beta-(25-35) using N-methylated derivatives: a general strategy to prevent amyloid formation. J. Biol. Chem. 275 (2000) 25109-25115
61. Hynd M.R., Scott H.L., and Dodd P.R. Glutamate(NMDA) receptor NR1 subunit mRNA expression in Alzheimer's disease. J. Neurochem. 78 (2001) 175-182
62. Ikai K., Ueda K., and Hayaishi O. Immunohistochemical demonstration of poly(adenosine diphosphate-ribose) in nuclei of various rat tissues. J. Histochem. Cytochem. 28 (1980) 670-676
63. Infante J., Llorca J., Mateo I., Rodriguez-Rodriguez E., Sanchez-Quintana C., Sanchez-Juan P., Fernandez-Viadero C., Pena N., Berciano J., and Combarros O. Interaction between poly(ADP-ribose) polymerase 1 and interleukin 1A genes is associated with Alzheimer's disease risk. Dement. Geriatr. Cogn. Disord. 23 (2007) 215-218
64. Iversen L.L., Mortishire-Smith R.J., Pollack S.J., and Shearman M.S. The toxicity in vitro of beta-amyloid protein. Biochem. J. 311 Pt 1 (1995) 1-16
65. Janicke R.U., Sprengart M.L., Wati M.R., and Porter A.G. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem. 273 (1998) 9357-9360
66. Jorm A.F., and Jolley D. The incidence of dementia: a meta-analysis. Neurology 51 (1998) 728-733
67. Kaminsky Y.G., and Kosenko E.A. Effects of amyloid-beta peptides on hydrogen peroxide-metabolizing enzymes in rat brain in vivo. Free Radic. Res. 42 (2008) 564-573
68. Kaminsky, Y.G., Kosenko, E.A., Mugantseva, E.A., Podolski, I.Y., Montoliu, C., Felipo, V., 2004. DNA fragmentation, poly(ADP-ribose) polymerase, NAD-synthetase, NAD-glycohydrolase, and p53 protein in nuclei from brain cells and Alzheimer's disease [Russian], Conference on "Basic Research for Medicine," Moscow, Slovo, pp. 15-17.
69. Kaminsky, Y.G., Poghosyan, A.S., Ovsepyan, A.A., Kosenko, E.A., Montoliu, C., and Felipo, V., 2005. DNA fragmentation and apoptotic factors in the brain of transgenic rats, Alzheimer's disease models, and blood cells from Alzheimer patients, Conference on "Basic Research for Medicine," Moscow, Slovo, pp. 19-21.
70. Kaminsky Y.G., Poghosyan A.S., Venediktova N.I., Podolski I.Y., Mugantseva E.A., Montoliu C., Felipo V., Maltsev A.V., and Kosenko E.A. DNA fragmentation and apoptotic factors in the brain of rat Alzheimer disease models and blood cells from Alzheimer patients. Gerontologia I. Geriatria 5 (2006) 65-70
71. Kaminsky Y.G., Venediktova N.I., Solomadin I.N., Marov N.V., and Kosenko E.A. Proteolytic enzymes in mitochondria, nuclei, lysosomes, and cytosol from neocortex, cerebellum and hippocampus after beta-amyloid injection to rats [Russian]. Biol. Membr. 24 (2007) 479-489
72. Kaneko I., Kubo T., and Morimoto K. [Neurotoxicity of beta-amyloid]. Nippon Yakurigaku Zasshi 115 (2000) 67-77
73. Kaneko I., Morimoto K., and Kubo T. Drastic neuronal loss in vivo by beta-amyloid racemized at Ser(26) residue: conversion of non-toxic [d-Ser(26)]beta-amyloid 1-40 to toxic and proteinase-resistant fragments. Neuroscience 104 (2001) 1003-1011
74. Kaneko I., Yamada N., Sakuraba Y., Kamenosono M., and Tutumi S. Suppression of mitochondrial succinate dehydrogenase, a primary target of beta-amyloid, and its derivative racemized at Ser residue. J. Neurochem. 65 (1995) 2585-2593
75. Kang J., Lemaire H.G., Unterbeck A., Salbaum J.M., Masters C.L., Grzeschik K.H., Multhaup G., Beyreuther K., and Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325 (1987) 733-736
76. Kimberly W.T., Zheng J.B., Guenette S.Y., and Selkoe D.J. The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner. J. Biol. Chem. 276 (2001) 40288-40292
77. Kluck R.M., Bossy-Wetzel E., Green D.R., and Newmeyer D.D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275 (1997) 1132-1136
78. Konig G., Monning U., Czech C., Prior R., Banati R., Schreiter-Gasser U., Bauer J., Masters C.L., and Beyreuther K. Identification and differential expression of a novel alternative splice isoform of the beta A4 amyloid precursor protein (APP) mRNA in leukocytes and brain microglial cells. J. Biol. Chem. 267 (1992) 10804-10809
79. Kosenko E., Kaminsky Y., Kaminsky A., Valencia M., Lee L., Hermenegildo C., and Felipo V. Superoxide production and antioxidant enzymes in ammonia intoxication in rats. Free Radic. Res. 27 (1997) 637-644
80. Kosenko E., Kaminsky Y., Lopata O., Muravyov N., Kaminsky A., Hermenegildo C., and Felipo V. Nitroarginine, an inhibitor of nitric oxide synthase, prevents changes in superoxide radical and antioxidant enzymes induced by ammonia intoxication. Metab. Brain Dis. 13 (1998) 29-41
81. Kosenko E., Kaminsky Y., Stavroskaya I.G., and Felipo V. Alteration of mitochondrial calcium homeostasis by ammonia-induced activation of NMDA receptors in rat brain in vivo. Brain Res. 880 (2000) 139-146
82. Kosenko E., Montoliu C., Giordano G., Kaminsky Y., Venediktova N., Buryanov Y., and Felipo V. Acute ammonia intoxication induces an NMDA receptor-mediated increase in poly(ADP-ribose) polymerase level and NAD metabolism in nuclei of rat brain cells. J. Neurochem. 89 (2004) 1101-1110
83. Kubo T., Kumagae Y., Miller C.A., and Kaneko I. Beta-amyloid racemized at the Ser26 residue in the brains of patients with Alzheimer disease: implications in the pathogenesis of Alzheimer disease. J. Neuropathol. Exp. Neurol. 62 (2003) 248-259
84. Kubo T., Nishimura S., Kumagae Y., and Kaneko I. In vivo conversion of racemized beta-amyloid ([d-Ser 26]A beta 1-40) to truncated and toxic fragments ([d-Ser 26]A beta 25-35/40) and fragment presence in the brains of Alzheimer's patients. J. Neurosci. Res. 70 (2002) 474-483
85. Kukull W.A., Higdon R., Bowen J.D., McCormick W.C., Teri L., Schellenberg G.D., van Belle G., Jolley L., and Larson E.B. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch. Neurol. 59 (2002) 1737-1746
86. Kuo Y.M., Kokjohn T.A., Watson M.D., Woods A.S., Cotter R.J., Sue L.I., Kalback W.M., Emmerling M.R., Beach T.G., and Roher A.E. Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism. Am. J. Pathol. 156 (2000) 797-805
87. Lane D. Awakening angels. Nature 394 (1998) 616-617
88. Lanz T.A., Himes C.S., Pallante G., Adams L., Yamazaki S., Amore B., and Merchant K.M. The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J. Pharmacol. Exp. Ther. 305 (2003) 864-871
89. Lee V.M., Balin B.J., Otvos Jr. L., and Trojanowski J.Q. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 251 (1991) 675-678
90. Lee H.J., Sorimachi H., Jeong S.Y., Ishiura S., and Suzuki K. Molecular cloning and characterization of a novel tissue-specific calpain predominantly expressed in the digestive tract. Biol. Chem. 379 (1998) 175-183
91. Lesne S., Ali C., Gabriel C., Croci N., MacKenzie E.T., Glabe C.G., Plotkine M., Marchand-Verrecchia C., Vivien D., and Buisson A. NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production. J. Neurosci. 25 (2005) 9367-9377
92. Levitt P., Pintar J.E., and Breakefield X.O. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc. Natl. Acad. Sci. U. S. A. 79 (1982) 6385-6389
93. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., and Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91 (1997) 479-489
94. Ling Y., Morgan K., and Kalsheker N. Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease. Int. J. Biochem. Cell Biol. 35 (2003) 1505-1535
95. Liu Q., and Zhao B. Nicotine attenuates beta-amyloid peptide-induced neurotoxicity, free radical and calcium accumulation in hippocampal neuronal cultures. Br. J. Pharmacol. 141 (2004) 746-754
96. Liu X., Kim C.N., Yang J., Jemmerson R., and Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86 (1996) 147-157
97. Liu F., Grundke-Iqbal I., Iqbal K., Oda Y., Tomizawa K., and Gong C.X. Truncation and activation of calcineurin A by calpain I in Alzheimer disease brain. J. Biol. Chem. 280 (2005) 37755-37762
98. Liu T., Qian W.J., Gritsenko M.A., Camp II D.G., Monroe M.E., Moore R.J., and Smith R.D. Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. J. Proteome. Res. 4 (2005) 2070-2080
99. Lockhart B.P., Benicourt C., Junien J.L., and Privat A. Inhibitors of free radical formation fail to attenuate direct beta-amyloid25-35 peptide-mediated neurotoxicity in rat hippocampal cultures. J. Neurosci. Res. 39 (1994) 494-505
100. Louw C., Gordon A., Johnston N., Mollatt C., Bradley G., and Whiteley C.G. Arginine deiminases: therapeutic tools in the etiology and pathogenesis of Alzheimer's disease. J. Enzyme Inhib. Med. Chem. 22 (2007) 121-126
101. Maddalena A.S., Papassotiropoulos A., Gonzalez-Agosti C., Signorell A., Hegi T., Pasch T., Nitsch R.M., and Hock C. Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer's disease determined by protein biochip technology. Neurodegener. Dis. 1 (2004) 231-235
102. Malyshev I.Y., Wiegant F.A., Mashina S.Y., Torshin V.I., Goryacheva A.V., Khomenko I.P., Kruglov S.V., Pokidyshev D.A., Popkova E.V., Pshennikova M.G., Vlasova M.A., Zelenina O.M., and Manukhina E.B. Possible use of adaptation to hypoxia in Alzheimer's disease: a hypothesis. Med. Sci. Monit. 11 (2005) HY31-HY38
103. Manczak M., Anekonda T.S., Henson E., Park B.S., Quinn J., and Reddy P.H. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 15 (2006) 1437-1449
104. Marcus D.L., Thomas C., Rodriguez C., Simberkoff K., Tsai J.S., Strafaci J.A., and Freedman M.L. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp. Neurol. 150 (1998) 40-44
105. Mason R.P., Estermyer J.D., Kelly J.F., and Mason P.E. Alzheimer's disease amyloid beta peptide 25-35 is localized in the membrane hydrocarbon core: x-ray diffraction analysis. Biochem. Biophys. Res. Commun. 222 (1996) 78-82
106. Matsui T., Ramasamy K., Ingelsson M., Fukumoto H., Conrad C., Frosch M.P., Irizarry M.C., Yuan J., and Hyman B.T. Coordinated expression of caspase 8, 3 and 7 mRNA in temporal cortex of Alzheimer disease: relationship to formic acid extractable abeta42 levels. J. Neuropathol. Exp. Neurol. 65 (2006) 508-515
107. Mattson M.P., Cheng B., Davis D., Bryant K., Lieberburg I., and Rydel R.E. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12 (1992) 376-389
108. Mattson M.P., Begley J.G., Mark R.J., and Furukawa K. Abeta25-35 induces rapid lysis of red blood cells: contrast with Abeta1-42 and examination of underlying mechanisms. Brain Res. 771 (1997) 147-153
109. MetLife Mature Market Institute. The MetLife Study of Alzheimer's disease: the caregiving experience (2006)
110. Mirzabekov T., Lin M.C., Yuan W.L., Marshall P.J., Carman M., Tomaselli K., Lieberburg I., and Kagan B.L. Channel formation in planar lipid bilayers by a neurotoxic fragment of the beta-amyloid peptide. Biochem. Biophys. Res. Commun. 202 (1994) 1142-1148
111. Mita S., Sadlock J., Herbert J., and Schon E.A. A cDNA specifying the human amyloid beta precursor protein (ABPP) encodes a 95-kDa polypeptide. Nucleic Acids Res. 16 (1988) 9351
112. Mogensen H.S., Beatty D.M., Morris S.J., and Jorgensen O.S. Amyloid beta-peptide(25-35) changes [Ca2+] in hippocampal neurons. Neuroreport 9 (1998) 1553-1558
113. Morais Cardoso S., Swerdlow R.H., and Oliveira C.R. Induction of cytochrome c-mediated apoptosis by amyloid beta 25-35 requires functional mitochondria. Brain Res. 931 (2002) 117-125
114. Moreira P.I., Santos M.S., Sena C., Nunes E., Seica R., and Oliveira C.R. CoQ10 therapy attenuates amyloid beta-peptide toxicity in brain mitochondria isolated from aged diabetic rats. Exp. Neurol. 196 (2005) 112-119
115. Moreira P.I., Cardoso S.M., Santos M.S., and Oliveira C.R. The key role of mitochondria in Alzheimer's disease. J. Alzheimers Dis. 9 (2006) 101-110
116. Multhaup G., Ruppert T., Schlicksupp A., Hesse L., Beher D., Masters C.L., and Beyreuther K. Reactive oxygen species and Alzheimer's disease. Biochem. Pharmacol. 54 (1997) 533-539
117. Murachi T., Tanaka K., Hatanaka M., and Murakami T. Intracellular Ca2+-dependent protease (calpain) and its high-molecular-weight endogenous inhibitor (calpastatin). Adv. Enzyme Regul. 19 (1980) 407-424
118. Murphy S.N., and Miller R.J. A glutamate receptor regulates Ca2+mobilization in hippocampal neurons. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 8737-8741
119. Nalivaeva N.N., Fisk L.R., Belyaev N.D., and Turner A.J. Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. Curr. Alzheimer Res. 5 (2008) 212-224
120. Ohyagi Y., Asahara H., Chui D.H., Tsuruta Y., Sakae N., Miyoshi K., Yamada T., Kikuchi H., Taniwaki T., Murai H., Ikezoe K., Furuya H., Kawarabayashi T., Shoji M., Checler F., Iwaki T., Makifuchi T., Takeda K., Kira J., and Tabira T. Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease. FASEB J. 19 (2005) 255-257
121. Pan G., O'Rourke K., and Dixit V.M. Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex. J. Biol. Chem. 273 (1998) 5841-5845
122. Parks J.K., Smith T.S., Trimmer P.A., Bennett Jr. J.P., and Parker Jr. W.D. Neurotoxic Abeta peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro. J. Neurochem. 76 (2001) 1050-1056
123. Pereira C., Santos M.S., and Oliveira C. Involvement of oxidative stress on the impairment of energy metabolism induced by A beta peptides on PC12 cells: protection by antioxidants. Neurobiol. Dis. 6 (1999) 209-219
124. Pike C.J., Burdick D., Walencewicz A.J., Glabe C.G., and Cotman C.W. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13 (1993) 1676-1687
125. Pike C.J., Walencewicz-Wasserman A.J., Kosmoski J., Cribbs D.H., Glabe C.G., and Cotman C.W. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J. Neurochem. 64 (1995) 253-265
126. Pompl P.N., Yemul S., Xiang Z., Ho L., Haroutunian V., Purohit D., Mohs R., and Pasinetti G.M. Caspase gene expression in the brain as a function of the clinical progression of Alzheimer disease. Arch. Neurol. 60 (2003) 369-376
127. Portelius E., Westman-Brinkmalm A., Zetterberg H., and Blennow K. Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J. Proteome. Res. 5 (2006) 1010-1016
128. Prives C., and Hall P.A. The p53 pathway. J. Pathol. 187 (1999) 112-126
129. Reddy P.H. Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapeutics. J. Biomed. Biotechnol. 2006 (2006) 31372
130. Risch N. Searching for genetic determinations in the new millennium. Nature 405 (2000) 847-856
131. Robakis N.K. Beta-amyloid and amyloid precursor protein: chemistry, molecular biology, and neuropathology. In: Terry R., Katzman R., and Bick K.L. (Eds). Alzheimer's Disease (1994), Raven Press, New York 317-326
132. Roher A.E., Lowenson J.D., Clarke S., Woods A.S., Cotter R.J., Gowing E., and Ball M.J. Beta-amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 10836-10840
133. Rossi L., Squitti R., Pasqualetti P., Marchese E., Cassetta E., Forastiere E., Rotilio G., Rossini P.M., and Finazzi-Agro A. Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by d-penicillamine. Neurosci. Lett. 329 (2002) 137-140
134. Rotter V., Abutbul H., and Ben-Ze'ev A. P53 transformation-related protein accumulates in the nucleus of transformed fibroblasts in association with the chromatin and is found in the cytoplasm of non-transformed fibroblasts. EMBO J. 2 (1983) 1041-1047
135. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., and Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2 (1996) 864-870
136. Schilling S., Zeitschel U., Hoffmann T., Heiser U., Francke M., Kehlen A., Holzer M., Hutter-Paier B., Prokesch M., Windisch M., Jagla W., Schlenzig D., Lindner C., Rudolph T., Reuter G., Cynis H., Montag D., Demuth H.U., and Rossner S. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nat. Med. 14 (2008) 1106-1111
137. Schuessel K., Leutner S., Cairns N.J., Muller W.E., and Eckert A. Impact of gender on upregulation of antioxidant defence mechanisms in Alzheimer's disease brain. J. Neural. Transm. 111 (2004) 1167-1182
138. Seiler N. Is ammonia a pathogenetic factor in Alzheimer's disease?. Neurochem. Res. 18 (1993) 235-245
139. Seiler N. Ammonia and Alzheimer's disease. Neurochem. Int. 41 (2002) 189-207
140. Seyidova D., Aliyev A., Rzayev N., Obrenovich M., Lamb B.T., Smith M.A., de la Torre J.C., Perry G., and Aliev G. The role of nitric oxide in the pathogenesis of brain lesions during the development of Alzheimer's disease. In Vivo 18 (2004) 325-333
141. Shapira R., Austin G.E., and Mirra S.S. Neuritic plaque amyloid in Alzheimer's disease is highly racemized. J. Neurochem. 50 (1988) 69-74
142. Shearman M.S., Ragan C.I., and Iversen L.L. Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of beta-amyloid-mediated cell death. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 1470-1474
143. Shen Y.X., Xu S.Y., Wei W., Sun X.X., Liu L.H., Yang J., and Dong C. The protective effects of melatonin from oxidative damage induced by amyloid beta-peptide 25-35 in middle-aged rats. J. Pineal. Res. 32 (2002) 85-89
144. Shoji M., Golde T.E., Ghiso J., Cheung T.T., Estus S., Shaffer L.M., Cai X.D., McKay D.M., Tintner R., Frangione B., and Younkin S. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258 (1992) 126-129
145. Siman R., Card J.P., and Davis L.G. Proteolytic processing of beta-amyloid precursor by calpain I. J. Neurosci. 10 (1990) 2400-2411
146. Sisodia S.S., Koo E.H., Beyreuther K., Unterbeck A., and Price D.L. Evidence that beta-amyloid protein in Alzheimer's disease is not derived by normal processing. Science 248 (1990) 492-495
147. Song W., Zhou L.J., Zheng S.X., and Zhu X.Z. Amyloid-beta 25-35 peptide induces expression of monoamine oxidase B in cultured rat astrocytes. Acta Pharmacol. Sin. 21 (2000) 557-563
148. Sorimachi H., Imajoh-Ohmi S., Emori Y., Kawasaki H., Ohno S., Minami Y., and Suzuki K. Molecular cloning of a novel mammalian calcium-dependent protease distinct from both m- and mu-types. Specific expression of the mRNA in skeletal muscle. J. Biol. Chem. 264 (1989) 20106-20111
149. Sorimachi H., Ishiura S., and Suzuki K. A novel tissue-specific calpain species expressed predominantly in the stomach comprises two alternative splicing products with and without Ca(2+)-binding domain. J. Biol. Chem. 268 (1993) 19476-19482
150. Sramek J.J., and Cutler N.R. Recent developments in the drug treatment of Alzheimer's disease. Drugs Aging 14 (1999) 359-373
151. Strosznajder J.B., Jesko H., and Strosznajder R.P. Effect of amyloid beta peptide on poly(ADP-ribose) polymerase activity in adult and aged rat hippocampus. Acta Biochim. Pol. 47 (2000) 847-854
152. Suo Z., Fang C., Crawford F., and Mullan M. Superoxide free radical and intracellular calcium mediate A beta(1-42) induced endothelial toxicity. Brain Res. 762 (1997) 144-152
153. Sutton E.T., Hellermann G.R., and Thomas T. Beta-amyloid-induced endothelial necrosis and inhibition of nitric oxide production. Exp. Cell Res. 230 (1997) 368-376
154. Terzi E., Holzemann G., and Seelig J. Reversible random coil-beta-sheet transition of the Alzheimer beta-amyloid fragment (25-35). Biochemistry 33 (1994) 1345-1350
155. Thomas T. Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease. Neurobiol. Aging 21 (2000) 343-348
156. Tsuruta T., Oh-Hashi K., Ueno Y., Kitade Y., Kiuchi K., and Hirata Y. RNAi knockdown of caspase-activated DNase inhibits rotenone-induced DNA fragmentation in HeLa cells. Neurochem. Int. 50 (2007) 601-606
157. Turner R.S. Alzheimer's disease. Semin. Neurol. 26 (2006) 499-506
158. Ueda K., Shinohara S., Yagami T., Asakura K., and Kawasaki K. Amyloid beta protein potentiates Ca2+ influx through L-type voltage-sensitive Ca2+ channels: a possible involvement of free radicals. J. Neurochem. 68 (1997) 265-271
159. Van Nostrand W.E., and Cunningham D.D. Purification of protease nexin II from human fibroblasts. J. Biol. Chem. 262 (1987) 8508-8514
160. Vaudry D., Cottet-Rousselle C., Basille M., Falluel-Morel A., Fournier A., Vaudry H., and Gonzalez B.J. Pituitary adenylate cyclase-activating polypeptide inhibits caspase-3 activity but does not protect cerebellar granule neurons against beta-amyloid (25-35)-induced apoptosis. Regul. Pept. 123 (2004) 43-49
161. Venediktova N.I., Kosenko E.A., and Kaminskii Iu G. [Antioxidant enzymes, hydrogen peroxide metabolism, and respiration in rat heart during experimental hyperammonemia]. Izv. Akad. Nauk. Ser. Biol. (2006) 351-357
162. Vigo-Pelfrey C., Lee D., Keim P., Lieberburg I., and Schenk D.B. Characterization of beta-amyloid peptide from human cerebrospinal fluid. J. Neurochem. 61 (1993) 1965-1968
163. Wang H., Xu H., Dyck L.E., and Li X.M. Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide(25-35)-induced oxidative stress and the ensuing apoptosis. J. Neurosci. Res. 81 (2005) 572-580
164. Wang X., Su B., Perry G., Smith M.A., and Zhu X. Insights into amyloid-beta-induced mitochondrial dysfunction in Alzheimer disease. Free Radic. Biol. Med. 43 (2007) 1569-1573
165. Weiss J.H., Pike C.J., and Cotman C.W. Ca2+ channel blockers attenuate beta-amyloid peptide toxicity to cortical neurons in culture. J. Neurochem. 62 (1994) 372-375
166. Westlund K.N., Krakower T.J., Kwan S.W., and Abell C.W. Intracellular distribution of monoamine oxidase A in selected regions of rat and monkey brain and spinal cord. Brain Res. 612 (1993) 221-230
167. Wolfe M.S., Xia W., Moore C.L., Leatherwood D.D., Ostaszewski B., Rahmati T., Donkor I.O., and Selkoe D.J. Peptidomimetic probes and molecular modeling suggest that Alzheimer's gamma-secretase is an intramembrane-cleaving aspartyl protease. Biochemistry 38 (1999) 4720-4727
168. Xiao X.Q., Wang R., Han Y.F., and Tang X.C. Protective effects of huperzine A on beta-amyloid(25-35) induced oxidative injury in rat pheochromocytoma cells. Neurosci. Lett. 286 (2000) 155-158
169. Xu J., Chen S., Ku G., Ahmed S.H., Chen H., and Hsu C.Y. Amyloid beta peptide-induced cerebral endothelial cell death involves mitochondrial dysfunction and caspase activation. J. Cereb. Blood Flow Metab. 21 (2001) 702-710
170. Yamada T., Sasaki H., Furuya H., Miyata T., Goto I., and Sakaki Y. Complementary DNA for the mouse homolog of the human amyloid beta protein precursor. Biochem. Biophys. Res. Commun. 149 (1987) 665-671
171. Yang S.F., Wu Z.J., Yang Z.Q., Wu Q., Gong Q.H., Zhou Q.X., and Shi J.S. Protective effect of ecdysterone on PC12 cells cytotoxicity induced by beta-amyloid25-35. Chin. J. Integr. Med. 11 (2005) 293-296
172. Yankner B.A., Dawes L.R., Fisher S., Villa-Komaroff L., Oster-Granite M.L., and Neve R.L. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 245 (1989) 417-420
173. Youdim M.B.H., Finberg J.P.M., and Tipton K.F. Monoamine oxidase. Handbook of experimental pharmacology (1988), Springer, Berlin 119-192
174. Zeng H., Chen Q., and Zhao B. Genistein ameliorates beta-amyloid peptide (25-35)-induced hippocampal neuronal apoptosis. Free Radic. Biol. Med. 36 (2004) 180-188
175. Zhao M., Su J., Head E., and Cotman C.W. Accumulation of caspase cleaved amyloid precursor protein represents an early neurodegenerative event in aging and in Alzheimer's disease. Neurobiol. Dis. 14 (2003) 391-403
176. Zhu X., Smith M.A., Perry G., and Aliev G. Mitochondrial failures in Alzheimer's disease. Am. J. Alzheimers Dis. Other. Demen. 19 (2004) 345-352
177. Zhu X., Perry G., Moreira P.I., Aliev G., Cash A.D., Hirai K., and Smith M.A. Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. J. Alzheimers Dis. 9 (2006) 147-153
178. Zou K., Gong J.S., Yanagisawa K., and Michikawa M. A novel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage. J. Neurosci. 22 (2002) 4833-4841